Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Repligen seeks European OK for MRI pancreas agent

This article was originally published in Scrip

Executive Summary

After winning a six-month priority review last month from the US FDA for SecreFlo (RG1068), a synthetic version of human secretin – with a decision expected by 21 June – Repligen has turned its eyes to the European market by submitting a marketing authorization application (MAA) for the drug as an agent to improve the detection of pancreatic duct abnormalities in patients with pancreatitis (scripintelligence, 27 February 2012).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts